Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENHANCE-1: Adjunctive Pimavanserin in Schizophrenia
NCT02970292Phase 3Completed
- Sponsor
- Acadia Pharmaceuticals
- Start
- Oct 2016
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing Pimavanserin with Placebo (2 arms). Primary endpoint: Positive and Negative Syndrome Scale Total Score at 6 weeks. Started Oct 2016; status: completed.
02
Drugs
pimavanserin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02970292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02970292.